Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial
<p><strong>Background</strong> Systemic sepsis is a major cause of death in preterm neonates. There are compelling theoretical reasons why treatment with haemopoietic colony-stimulating factors might reduce sepsis and improve outcomes, and as a consequence these agents have entered...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Jezik: | English |
| Izdano: |
Elsevier
2009
|